Axonics Modulation Technologies (AXNX) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Axonics® Reports Fourth Quarter and Fiscal Year 2020 Results
February 25, 2021 4:05 PM ESTIRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported results for the fourth quarter and fiscal year ended December 31, 2020.
Raymond W. Cohen, Axonics CEO, said, In the first year of Axonics commercial launch in the United States, we exceeded our ambitious goals despite the pandemic and only having approximately ten months of selling time. We are grateful for the overwhelmingly positive response from... More
